ALFA-LAVAL ANTI-STONE ACID DETERGENT LIQUID LF HEAVY DUTY Ավստրալիա - անգլերեն - APVMA (Australian Pesticides and Veterinary Medicines Authority)

alfa-laval anti-stone acid detergent liquid lf heavy duty

alfa laval pty ltd - nitric acid | sulfamic acid - dairy cleanser - milking equipment | milking machine - residue, dirt in milking equipment

STRENSIQ asfotase alfa rch 28 mg/0.70 ml solution for injection vial Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

strensiq asfotase alfa rch 28 mg/0.70 ml solution for injection vial

alexion pharmaceuticals australasia pty ltd - asfotase alfa, quantity: 40 mg/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate heptahydrate; water for injections; monobasic sodium phosphate monohydrate - strensiq (asfotase alfa, rch) is indicated as enzyme replacement therapy in patients with paediatric-onset hypophosphatasia.

STRENSIQ asfotase alfa rch 18 mg/0.45 ml solution for injection vial Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

strensiq asfotase alfa rch 18 mg/0.45 ml solution for injection vial

alexion pharmaceuticals australasia pty ltd - asfotase alfa, quantity: 40 mg/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate heptahydrate; water for injections; monobasic sodium phosphate monohydrate - strensiq (asfotase alfa, rch) is indicated as enzyme replacement therapy in patients with paediatric-onset hypophosphatasia.

STRENSIQ asfotase alfa rch 12 mg/0.30 ml solution for injection vial Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

strensiq asfotase alfa rch 12 mg/0.30 ml solution for injection vial

alexion pharmaceuticals australasia pty ltd - asfotase alfa, quantity: 40 mg/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate heptahydrate; water for injections; monobasic sodium phosphate monohydrate - strensiq (asfotase alfa, rch) is indicated as enzyme replacement therapy in patients with paediatric-onset hypophosphatasia.

AFOLIA follitropin alfa (rch) 300 IU/0.5 mL (22 microgram) solution for injection cartridge in a pre-filled pen Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

afolia follitropin alfa (rch) 300 iu/0.5 ml (22 microgram) solution for injection cartridge in a pre-filled pen

gedeon richter australia pty ltd - follitropin alfa, quantity: 300 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- afolia is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- afolia in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- afolia is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

AFOLIA follitropin alfa (rch) 225 IU/0.375 mL (16.5 microgram) solution for injection cartridge in a pre-filled pen Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

afolia follitropin alfa (rch) 225 iu/0.375 ml (16.5 microgram) solution for injection cartridge in a pre-filled pen

gedeon richter australia pty ltd - follitropin alfa, quantity: 225 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- afolia is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- afolia in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- afolia is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

STRENSIQ asfotase alfa rch 40 mg/1.00 ml solution for injection  vial Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

strensiq asfotase alfa rch 40 mg/1.00 ml solution for injection vial

alexion pharmaceuticals australasia pty ltd - asfotase alfa, quantity: 40 mg/ml - injection, solution - excipient ingredients: sodium chloride; dibasic sodium phosphate heptahydrate; water for injections; monobasic sodium phosphate monohydrate - strensiq (asfotase alfa, rch) is indicated as enzyme replacement therapy in patients with paediatric-onset hypophosphatasia.

STRENSIQ asfotase alfa rch 80 mg/0.80 mL injection solution vial Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

strensiq asfotase alfa rch 80 mg/0.80 ml injection solution vial

alexion pharmaceuticals australasia pty ltd - asfotase alfa, quantity: 100 mg/ml - injection, solution - excipient ingredients: dibasic sodium phosphate heptahydrate; sodium chloride; monobasic sodium phosphate monohydrate; water for injections - strensiq (asfotase alfa, rch) is indicated as enzyme replacement therapy in patients with paediatric-onset hypophosphatasia.

BEMFOLA follitropin alfa (rch) 450 IU/0.75 mL (33 microgram) solution for injection cartridge in a pre-filled pen Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

bemfola follitropin alfa (rch) 450 iu/0.75 ml (33 microgram) solution for injection cartridge in a pre-filled pen

gedeon richter australia pty ltd - follitropin alfa, quantity: 450 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- bemfola is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- bemfola in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.

BEMFOLA follitropin alfa (rch) 300 IU/0.5 mL (22 microgram) solution for injection cartridge in a pre-filled pen Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

bemfola follitropin alfa (rch) 300 iu/0.5 ml (22 microgram) solution for injection cartridge in a pre-filled pen

gedeon richter australia pty ltd - follitropin alfa, quantity: 300 iu - injection, solution - excipient ingredients: poloxamer; sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; methionine; phosphoric acid; thymidine; trypsin - in adult women:,- bemfola is indicated for the treatment of anovulatory infertility in women who have been unresponsive to clomiphene citrate or where clomiphene citrate is contraindicated,- controlled ovarian hyperstimulation in women undergoing assisted reproductive technologies,- bemfola in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level <1.2 iu/l.,in adult men:,- bemfola is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in gonadotrophin-deficient men in whom hcg alone is ineffective.